The National Cancer Institute is offering a grant to merge Phase 2 clinical trials with the Experimental Therapeutics Clinical Trials Network (ETCTN) to advance experimental cancer therapeutics. This grant aims to integrate Phase 2 capabilities into the existing ETCTN structure for efficient conduct of early clinical trials, ultimately speeding up the delivery of new cancer therapies. Applications are open to current ETCTN UM1 awardees to enhance trial management and accelerate the development of innovative cancer treatments. Closing Date: Jun 19, 2015.
Opportunity ID: 275340
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-15-501 |
| Funding Opportunity Title: | Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | 10 |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 23, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jun 19, 2015 |
| Current Closing Date for Applications: | Jun 19, 2015 |
| Archive Date: | Jul 20, 2015 |
| Estimated Total Program Funding: | $7,200,000 |
| Award Ceiling: | $560,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Private institutions of higher education Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Only current ETCTN UM1 awardees may submit revision applications invited by this FOA (including Canadian recipients of the ETCTN award). See full announcement for full details. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to enhance the NCI-supported early development of experimental cancer therapeutics by merging the Phase 2 clinical trials program with the Experimental Therapeutics Clinical Trials Network (ETCTN, funded through RFA-CA-13-006) that is currently focused on Phase 1 clinical trials.
The FOA invites revision applications from ETCTN UM1 awardees to expand the scope of activities by adding capabilities to conduct Phase 2 clinical trials. The goal is to integrate Phase 2 infrastructure and expertise to create a unified network for an efficient and comprehensive conduct of early clinical trials. This integration of the Phase 2 capabilities into the new ETCTN structure will allow for more seamless advancement of experimental agents through early stages of development. Ultimately, the expected increased efficiency of clinical trial management is expected to accelerate the delivery of new cancer therapies to the public. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-501.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-C | FORMS-C | PKG00215720 | May 19, 2015 | Jun 19, 2015 | View |
Package 1
Mandatory forms
275340 RR_SF424_2_0-2.0.pdf
275340 PHS398_ResearchPlan_2_0-2.0.pdf
275340 PHS398_CoverPageSupplement_2_0-2.0.pdf
275340 RR_Budget_1_3-1.3.pdf
275340 RR_KeyPersonExpanded_2_0-2.0.pdf
275340 RR_OtherProjectInfo_1_3-1.3.pdf
275340 PerformanceSite_2_0-2.0.pdf
Optional forms
275340 PlannedReport-1.0.pdf
275340 PHS398_CumulativeInclusionReport-1.0.pdf
275340 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
